IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

NGUYEN et al.

Appl. No. 09/227,881240

Filed: January 11, 1999

For: Nuc

Nucleic Acids, Kits and Methods

for the Diagnosis, Prognosis and Treatment of Glaucoma and

Related Disorders

Art Unit: 1635

Examiner: Shibuya, M. L.

Atty. Docket: 07425.0057.00US00

Amendment And Reply Under 37 C.F.R. § 1.111

Commissioner for Patents Washington, D.C. 20231

Sir:

In reply to the Office Action dated December 19, 2000, (PTO Prosecution File Wrapper Paper No. 13), Applicants submit the following Amendment and Remarks.

It is not believed that extensions of time are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 01-2510.

Amendments

Please amend the application as follows:

In the Specification:

Please amend the specification as follows:

Please delete the 2 paragraphs and their headings that begin on page 1, line 4 of the specification, and end on line 12.

Please insert the following paragraphs at page 1, line 13 of the specification as currently filed:

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. Patent Application serial no. 08/938,669, filed September 26, 1997, now issued as U.S. Patent No. 6,171,788, specifically incorporated by reference herein, which is a continuation-in-part of U.S. Patent Application serial no. 08/791,154, filed January 28, 1997, now abandoned, also specifically incorporated by reference herein.

FIELD OF THE INVENTION

The present invention relates to the field of diagnostic and prognostic methods and kits, treatments, and compositions useful in understanding and identifying glaucoma, related intraocular pressure-disorders, and steroid sensitivity.

